Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer

Holly Chitwood, Adria Myers

Research output: Contribution to journalArticlepeer-review

Abstract

The emergence of molecular analysis approaches that use circulating tumor DNA (ctDNA) to measure minimal residual disease is shifting the management of colorectal cancer and many solid tumor cancers. Analysis of ctDNA has sev.

Original languageEnglish
Pages (from-to)369-374
Number of pages6
JournalClinical Journal of Oncology Nursing
Volume27
Issue number4
DOIs
StatePublished - Jul 20 2023

Keywords

  • circulating tumor DNA
  • colorectal cancer
  • ctDNA
  • minimal residual disease

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Use of Circulating Tumor DNA to Monitor Minimal Residual Disease Among Patients With Colorectal Cancer'. Together they form a unique fingerprint.

Cite this